These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12393557)

  • 1. Common mechanism for oncogenic activation of MLL by forkhead family proteins.
    So CW; Cleary ML
    Blood; 2003 Jan; 101(2):633-9. PubMed ID: 12393557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.
    So CW; Cleary ML
    Mol Cell Biol; 2002 Sep; 22(18):6542-52. PubMed ID: 12192052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
    DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
    Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.
    DiMartino JF; Ayton PM; Chen EH; Naftzger CC; Young BD; Cleary ML
    Blood; 2002 May; 99(10):3780-5. PubMed ID: 11986236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The small oligomerization domain of gephyrin converts MLL to an oncogene.
    Eguchi M; Eguchi-Ishimae M; Greaves M
    Blood; 2004 May; 103(10):3876-82. PubMed ID: 14751928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.
    So CW; Lin M; Ayton PM; Chen EH; Cleary ML
    Cancer Cell; 2003 Aug; 4(2):99-110. PubMed ID: 12957285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
    Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
    Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
    Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
    Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.
    Ayton PM; Cleary ML
    Oncogene; 2001 Sep; 20(40):5695-707. PubMed ID: 11607819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of AF3p21, a new member of mixed lineage leukemia (MLL) fusion partner proteins-implication for MLL-induced leukemogenesis.
    Sano K
    Leuk Lymphoma; 2001 Aug; 42(4):595-602. PubMed ID: 11697487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9.
    So CW; Karsunky H; Wong P; Weissman IL; Cleary ML
    Blood; 2004 Apr; 103(8):3192-9. PubMed ID: 15070702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23).
    Borkhardt A; Repp R; Haas OA; Leis T; Harbott J; Kreuder J; Hammermann J; Henn T; Lampert F
    Oncogene; 1997 Jan; 14(2):195-202. PubMed ID: 9010221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice.
    So CW; Karsunky H; Passegué E; Cozzio A; Weissman IL; Cleary ML
    Cancer Cell; 2003 Feb; 3(2):161-71. PubMed ID: 12620410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.
    Ono R; Nakajima H; Ozaki K; Kumagai H; Kawashima T; Taki T; Kitamura T; Hayashi Y; Nosaka T
    J Clin Invest; 2005 Apr; 115(4):919-29. PubMed ID: 15761502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily.
    Hillion J; Le Coniat M; Jonveaux P; Berger R; Bernard OA
    Blood; 1997 Nov; 90(9):3714-9. PubMed ID: 9345057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX.
    Slany RK; Lavau C; Cleary ML
    Mol Cell Biol; 1998 Jan; 18(1):122-9. PubMed ID: 9418860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional activation is a key function encoded by MLL fusion partners.
    Zeisig BB; Schreiner S; García-Cuéllar MP; Slany RK
    Leukemia; 2003 Feb; 17(2):359-65. PubMed ID: 12592336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.
    Ayton PM; Cleary ML
    Genes Dev; 2003 Sep; 17(18):2298-307. PubMed ID: 12952893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein.
    Ayton PM; Chen EH; Cleary ML
    Mol Cell Biol; 2004 Dec; 24(23):10470-8. PubMed ID: 15542854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FEL (AF-4) protein donates transcriptional activation sequences to Hrx-Fel fusion proteins in leukemias containing T(4;11)(Q21;Q23) chromosomal translocations.
    Morrissey JJ; Raney S; Cleary ML
    Leuk Res; 1997 Oct; 21(10):911-7. PubMed ID: 9403001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.